Filtered By:
Therapy: Stem Cell Therapy

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 2351 results found since Jan 2013.

The Role of Stem Cells in the Therapy of Stroke
CONCLUSION: Although further research in this field is required, post stroke brain recovery supported by exogenous stem cells seems to be promising future therapy revolutionizing modern neurology.PMID:34365923 | DOI:10.2174/1570159X19666210806163352
Source: Current Neuropharmacology - August 9, 2021 Category: Drugs & Pharmacology Authors: Maria Ejma Natalia Madetko Anna Brzecka Piotr Alster S ławomir Budrewicz Magdalena Koszewicz Marta Misiuk-Hoj ło Irina K Tomilova Siva G Somasundaram Cecil E Kirkland Gjumrakch Aliev Source Type: research

Intestinal Epithelial Stem Cell Transplants as a Novel Therapy for Cerebrovascular Stroke
Brain Behav Immun. 2022 Oct 31:S0889-1591(22)00420-2. doi: 10.1016/j.bbi.2022.10.015. Online ahead of print.ABSTRACTAlmost 2/3rds of stroke survivors exhibit vascular cognitive impairment and a third of stroke patients will develop dementia 1-3 years after stroke. These dire consequences underscore the need for effective stroke therapies. In addition to its damaging effects on the brain, stroke rapidly dysregulates the intestinal epithelium, resulting in elevated blood levels of inflammatory cytokines and toxic gut metabolites due to a 'leaky' gut. We tested whether repairing the gut via intestinal epithelial stem cell (IE...
Source: Brain, Behavior, and Immunity - November 3, 2022 Category: Neurology Authors: Kathiresh Kumar Mani Yumna El-Hakim Taylor E Branyan Nadia Samiya Sivani Pandey Maria T Grimaldo Ali Habbal Anna Wertz Farida Sohrabji Source Type: research

Predictive Risk Factors of In-Hospital Mortality Following Acute Stroke in the United States: Data from the Nationwide Inpatient Database, 2006-2010 (P02.015)
CONCLUSIONS: The rate of in-hospital mortality is relatively high following acute stroke (8.42%). We identified multiple risk factors of in-hospital mortality in acute stroke patients. The strongest risk factor is the type stroke (hemorrhagic). The present finding suggests that patients at increased risk of mortality can be identified and additional treatment for prevention might be warranted.Disclosure: Dr. Naderi has nothing to disclose. Dr. Abcede has nothing to disclose. Dr. Al-Khoury has nothing to disclose. Dr. Mozaffar has received personal compensation for activities with California Stem Cell Inc., NuFactor, Cresce...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Naderi, N., Abcede, H., Al-Khoury, L., Mozaffar, T., Jain, V. Tags: P02 Cerebrovascular Disease II Source Type: research

Bioluminescence imaging of stroke-induced endogenous neural stem cell response.
In conclusion, we developed and validated a novel imaging technique that unequivocally demonstrates that nestin(+) eNSCs originating from the SVZ respond to stroke injury by increased proliferation, migration towards the infarct region and differentiation into both astrocytes and neurons. In addition, this new approach allows non-invasive and specific monitoring of eNSCs over time, opening perspectives for preclinical evaluation of candidate stroke therapeutics. PMID: 24878507 [PubMed - as supplied by publisher]
Source: Neurobiology of Disease - May 27, 2014 Category: Neurology Authors: Vandeputte C, Reumers V, Aelvoet SA, Thiry I, De Swaef S, Van Den Haute C, Pascual-Brazo J, Farr TD, Vande Velde G, Hoehn M, Himmelreich U, Van Laere K, Debyser Z, Gijsbers R, Baekelandt V Tags: Neurobiol Dis Source Type: research

NF-κB is involved in brain repair by stem cell factor and granulocyte-colony stimulating factor in chronic stroke.
Abstract Chronic stroke is the phase of brain recovery and repair generally beginning 3 months after stroke onset. No pharmaceutical approach is currently available to enhance brain repair in the chronic stroke. We have previously determined the therapeutic effects of stem cell factor (SCF) and granulocyte-colony stimulating factor (G-CSF) alone or in combination (SCF+G-CSF) in an animal model of chronic stroke and demonstrated that only SCF+G-CSF induces long-term functional recovery. However, the mechanism underlying the SCF+G-CSF-induced brain repair in chronic stroke remains largely elusive. In the present stu...
Source: Experimental Neurology - September 30, 2014 Category: Neurology Authors: Cui L, Duchamp NS, Boston DJ, Ren X, Zhang X, Hu H, Zhao LR Tags: Exp Neurol Source Type: research

Intranasal Delivery of Bone Marrow Mesenchymal Stem Cells Improved Neurovascular Regeneration and Rescued Neuropsychiatric Deficits after Neonatal Stroke in Rats.
Abstract Neonatal stroke is a major cause of mortality and long-term morbidity in infants and children. Currently very limited therapeutic strategies are available to protect the developing brain against ischemic damage and promote brain repairs for pediatric patients. Moreover, children who experienced neonatal stroke often have developmental social behavior problems. Cellular therapy using bone marrow mesenchymal stem cells (BMSCs) has emerged as a regenerative therapy after stroke. In the present investigation, neonatal stroke of postnatal day 7 (P7) rat pups was treated with non-invasive and brain specific int...
Source: Cell Transplantation - February 2, 2015 Category: Cytology Authors: Wei ZZ, Gu X, Ferdinand A, Lee JH, Ji X, Ji XM, Yu SP, Wei L Tags: Cell Transplant Source Type: research

Fibrinogen reduction and motor function improvement by hematopoietic growth factor treatment in chronic stroke in aged mice: a treatment frequency study.
This study provides new insight into understanding of the potential contribution of SCF+G-CSF in both reducing the risk of recurrent ischemic stroke and enhancing stroke recovery. PMID: 26817662 [PubMed - as supplied by publisher]
Source: Cell Transplantation - January 26, 2016 Category: Cytology Authors: Liu Y, Popescu M, Longo S, Gao M, Wang D, McGillis S, Zhao LR Tags: Cell Transplant Source Type: research

Sex differences in stroke therapies.
Abstract Stroke is the fifth leading cause of death and acquired disability in aged populations. Women are disproportionally affected by stroke, having a higher incidence and worse outcomes than men. Numerous preclinical studies have discovered novel therapies for the treatment of stroke, but almost all of these have been shown to be unsuccessful in clinical trials. Despite known sex differences in occurrence and severity of stroke, few preclinical or clinical therapeutics take into account possible sex differences in treatment. Reanalysis of data from studies of tissue plasminogen activator (tPA), the only curren...
Source: Cell Research - November 23, 2016 Category: Cytology Authors: Sohrabji F, Park MJ, Mahnke AH Tags: J Neurosci Res Source Type: research